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Abstract
Background: Serum concentration of fetuin A/α2HS-glycoprotein (AHSG) is a good indicator of liver cell function and 1-month
mortality in patients with alcoholic liver cirrhosis and liver cancer. We intended to determine whether decreased serum AHSG
levels are associated with long-term mortality and whether the follow-up of serum AHSG levels can add to the predictive value
of the Child-Pugh (CP) and MELD scores.
Methods: We determined serum AHSG concentrations in 89 patients by radial immunodiffusion. Samples were taken at the
time of enrolment and in the 1st, 3rd, 6th, and the 12th month thereafter.
Results: Forty-one patients died during the 1-year follow-up period, 37 of them had liver failure. Data of these patients were
analysed further. Deceased patients had lower baseline AHSG levels than the 52 patients who survived (293 ± 77 vs. 490 ± 106
μg/ml, mean ± SD, p < 0.001). Of all laboratory parameters serum AHSG level, CP and MELD scores showed the greatest
difference between deceased and survived patients. The cutoff AHSG level 365 μg/ml could differentiate between deceased and
survived patients (AUC: 0.937 ± 0.025, p < 0.001, sensitivity: 0.865, specificity: 0.942) better than the MELD score of 20 (AUC:
0.739 ± 0.052, p < 0.001, sensitivity: 0.595, specificity: 0.729). Initial AHSG concentrations < 365 μg/ml were associated with
high mortality rate (91.4%, relative risk: 9.874, 95% C.I.: 4.258–22.898, p < 0.001) compared to those with ≥ 365 μg/ml (9.3%).
Fourteen out of these 37 fatalities occurred during the first month of observation. During months 1–12 low AHSG
concentration proved to be a strong indicator of mortality (relative risk: 9.257, 95% C.I.: 3.945–21.724, p < 0.001). Multiple
logistic regression analysis indicated that decrease of serum AHSG concentration was independent of all variables that differed
between survived and deceased patients during univariate analysis. Multivariate analysis showed that correlation of low serum
AHSG levels with mortality was stronger than that with CP and MELD scores. Patients with AHSG < 365 μg/ml had significantly
shortened survival both in groups with MELD < 20 and MELD ≥ 20 (p < 0.0001 and p = 0.0014, respectively).
Conclusion: Serum AHSG concentration is a reliable and sensitive indicator of 1-year mortality in patients with alcoholic liver
cirrhosis that compares well to the predictive value of CP score and may further improve that of MELD score.
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Human fetuin A/α2HS-glycoprotein (AHSG) is a serum
glycoprotein with a concentration around 450–600 μg/ml
in healthy persons. AHSG is a negative acute phase reac-
tant [1], accumulates in bone tissue and prevents unto-
ward calcification [2,3]. Mice knocked-out for AHS gene
exhibit extraosseal calcification [4]. AHSG is a natural
antagonist of growth factors like insulin [5,6], transform-
ing growth factor β (TGF-β) [7], hepatocyte growth factor/
scatter factor (HGF/SF) [8] and inhibits lymphocyte blas-
tic transformation [9]. These findings indicate that AHSG
may be involved in tissue regeneration [8].
Since serum AHSG is produced exclusively by hepatocytes
in adults [10] and its concentration decreases during the
acute phase reaction we investigated its changes in
patients with liver diseases [11,12]. We found low serum
AHSG levels in patients with acute alcoholic hepatitis,
acute drug-induced hepatitis, chronic autoimmune hepa-
titis, fatty liver, alcoholic and primary biliary cirrhosis,
and hepatocellular cancer [11-13]. Alterations were most
marked in patients with alcoholic liver cirrhosis and hepa-
tocellular cancer [11,12]. In these patients short-term (i.e.
for one month) follow-up indicated that serum concen-
tration of AHSG is an excellent indicator of liver function
and mortality [11]. Serum AHSG levels showed by far the
greatest difference when we compared laboratory param-
eters of deceased and survived patients with liver cirrhosis
and cancer. Decreased levels (≤ 300 μg/ml) were associ-
ated with high mortality rate (52%, relative risk: 5.497, p
< 0.0001). In this respect serum AHSG was the best of all
laboratory parameters studied. Multiple logistic regres-
sion analysis indicated that serum AHSG level was inde-
pendent of all parameters that were pathologic in
deceased patients [11].
In this study we tried to determine the usefulness of serum
AHSG levels for the long-term (i.e. up to 1 year) follow-up
of patients with alcoholic liver cirrhosis. We intended to
compare the predictive value of serum AHSG levels to
those of the Child-Pugh (CP) and the Model for End-Stage
Liver Disease (MELD) scores. Both scores have been
widely used to estimate the outcome of patients with end-
stage liver disease, including alcoholic cirrhosis [14-16].
Herein we report that low serum AHSG concentration is a
reliable and sensitive indicator of 1-year mortality in
patients with alcoholic liver cirrhosis, comparing to the
CP score and may further improve the predictive value of
the MELD score.
Methods
Patients
Ninety-three patients with alcoholic liver cirrhosis (52
men, 41 women, mean age: 54 ± 13 years, mean ± SD)
were tested. They gave written consent approved by the
Ethical Committee of Semmelweis University. Besides his-
tory and appropriate clinical symptoms the diagnosis was
established by abdominal ultrasonography, and liver
scan. Exclusion criteria were as follows: cirrhosis of viral
origin (HBsAg and anti-HCV positivity), or autoimmune
aetiology (antinuclear and anti-smooth muscle antibod-
ies), liver cancer, and treatment with hepatotoxic drugs.
For ethical reasons liver biopsy was not performed. Blood
samples were taken at the time of enrolment and in the
1st, 3rd, 6th and 12th months thereafter. Patients with alco-
holic liver cirrhosis were only on supportive therapy (diu-
retics, beta-blockers).
The MELD score was calculated according to the formula
of Kamath et al. (3.8 * ln serum bilirubine [mg/dl] + 11.2
* ln INR + 9.6 * ln serum creatinine [mg/dl] + 6.4) [16].
The CP score of patients was calculated by rating the fol-
lowing parameters between 1 and 3: ascites, encephalop-
athy, prothrombin time (< 15, 15–17, > 17s), serum
bilirubin (< 2, 2–3, > 3 mg/dl), serum albumin (> 35, 28–
35, < 28 g/l) [14,15]. There were 53 patients with grade 1,
20 with grade 2 and 16 with grade 3 encephalopathy, 27
patients with grade 1, 36 with grade 2, and 26 with grade
3 ascites, and 16 patients with CP score 5–6, 46 with 7–9,
and 30 with 10 or higher, respectively.
Determination of serum AHSG concentration
Serum levels of AHSG were determined by radial immun-
odiffusion (RID) using 10 × 10 cm slides as described pre-
viously [11]. In brief, 5 μl of patient's sera diluted to 1:4
was applied in 11.5 ml of Litex agarose gel (Sigma). Serum
samples (1:4 dilution) with known concentrations of
AHSG served as standards. The incubation was done at
room temperature for 48 hours. We used anti-AHSG (IgG
fraction, Incstar, Cat No. 81931, 13.7 mg/ml, in a final
concentration of 84 μl/11.5 ml gel) as antibody. The vari-
ation coefficient of the test was 3.6%.
Other laboratory determinations
The determination of the erythrocyte sedimentation rate
(ESR), hematocrit, hemoglobin, white blood cell (WBC),
granulocyte and platelet (PLT) count, serum bilirubin,
serum aspartate aminotransferase (ASAT), alanine ami-
notransferase (ALAT), alkaline phosphatase activities,
International Normalisation Rate (INR), total serum pro-
tein and albumin concentrations was performed using
conventional standardized methods. Serum levels of α2-
macroglobulin, transferrin (TF), haptoglobin, and α1-
acid glycoprotein/orosomucoid (OROSO) were measured
by RID. Variation coefficients were 5.0%, and 4.2% for
OROSO and TF measurements, respectively. C-reactive
protein (CRP) concentration was determined by a parti-
cle-enhanced immunoturbidimetric assay (Roche Cobas
Integra 4000®). The detection limit of the assay was 0.07Page 2 of 9
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mean value.
Statistical analysis
Paired and unpaired data were analysed by the Wilcoxon
and Mann-Whitney U tests, respectively. Correlation stud-
ies were done by the rank correlation analysis (Spear-
man). Contingency tables were analysed by the Fisher's
exact test. Patients' survival was calculated by the Kaplan-
Meyer test and life table analysis. These tests, the multiple
logistic regression, and the receiver operating characteris-
tic (ROC) curve analyses were performed with the SPSS
v.11.5 statistical program. The level of p < 0.01 was con-
sidered significant.
Results
Relationship between initial serum AHSG concentration 
and 1-year survival of patients with alcoholic liver cirrhosis
During the one-year follow up 41 out of the 93 patients
died. Four patients died of intercurrent illnesses unrelated
to liver disease (2 of acute left ventricular failure, 1 of
myocardial infarction, and 1 of pneumonia, respectively).
The remaining 37 patients died of liver failure, and their
data were analysed further. Table 1Column A shows the
laboratory data of patients according to the outcome at
the end of the one-year follow-up period. Compared to
survivors we found significantly lower baseline values of
hematocrit, albumin, TF and AHSG concentrations and
significantly higher creatinine, bilirubine, INR, CP and
MELD score values in deceased patients. Serum AHSG
level showed one of the greatest differences among all lab-
oratory parameters tested. We observed significantly posi-
tive correlations of AHSG with hematocrit (r = 0.406, p=
0.001), albumin (r = 0.366, p = 0.002), TF (r = 0.529, p <
0.001), and negative correlations with serum creatinine (r
= -0.312, p = 0.006), INR (r = -0.467, p < 0.001), CRP (r =
-0.405, p = 0.001), the MELD (r = -0.342, p = 0.001) and
CP scores (r = -0.522, p < 0.001) whereas no significant
correlations were found with the other parameters tested.
Determination of the predictive accuracy of serum AHSG 
concentration
We used the ROC curve analysis to determine the optimal
cutoff value and test the discrimination ability of serum
AHSG concentration (Table 2, Column A). Based on this
curve, the AHSG concentration of 365 μg/ml has been
identified as the optimal cutoff value for stratification of
our patients. At 365 μg/ml the relative risk, sensitivity and
specificity were higher than those of the cutoff value 300
μg/ml, which was used at the short-term study.
Initial AHSG levels below 365 μg/ml were associated with
a significantly higher risk of mortality than those with val-
ues above this level (Table 3A). This finding was con-
firmed by the Kaplan-Meyer analysis of patients' survival
(Figure 1). The calculated mean survival time of patients
with AHSG levels below and above 365 μg/ml was 3 ± 1
months (mean ± S.E., 95% C.I.: 2 – 4) and 11 ± 1 months
(95% C.I.: 11 – 12, p < 0.0001), respectively (log rank
analysis). Life table analysis resulted in a median survival
of 3.27 months in the former and over 12 months in the
latter group, respectively (p < 0.0001). The hazard rate of
fatal outcome increased with time in patients with serum
AHSG < 365 μg/ml but not in those with higher AHSG
levels (Table 4).
There were 6 patients with concomitant alcoholic hepati-
tis (serum AHSG: 405 ± 85 μg/ml, mean ± S.D.), whose
values did not differ significantly from those without it
(434 ± μg/ml, n = 83, p = 0.447). In patients with alco-
holic hepatitis baseline AHSG increased to 454 ± 101 μg/
ml (p = 0.500). The statistical comparison (Wilcoxon
test), however, is not relevant due to small sample size.
Seven patients out of the 89 with alcoholic cirrhosis con-
tinued to drink. Their serum AHSG level (259 ± 97 μg/ml,
mean ± S.D.) was significantly lower than those who were
abstinent (418 ± 129 μg/ml, n = 82, p = 0.003). Six of
them died during the observation period. The only one
survivor had baseline AHSG concentration above 365 μg/
ml.
On enrolment 4 patients had infection: one spontaneous
bacterial peritonitis, one cholangitis, one erysipelas, and
one uroinfection, respectively. Their mean baseline serum
AHSG level (445 ± 126 μg/ml, mean ± SD) increased to
475 ± 171 μg/ml by the time the next sample was taken
(Wilcoxon test, p = 0.465).
Serum AHSG levels did not vary considerably throughout
the entire observation period as it is illustrated in Figure 2.
Patients (n = 75) were divided to four quartiles according
to their baseline AHSG levels. Patients in these four quar-
tiles were followed and their final AHSG levels were com-
pared to their baseline quartile values. Final AHSG values
were within the range of the baseline quartiles (signifi-
cance of difference between baseline and final values in
quartiles 1, 2, 3, and 4 were p = 0.022, p = 0.248, p =
0.897, and p = 0.126, respectively). Patients with baseline
values below 300 μg/ml almost never reached values
above 350 μg/ml, and vice versa.
Serum AHSG concentration is an independent predictor of 
long-term mortality
Low serum AHSG concentration was associated with high
mortality in patients studied. Comparison of laboratory
data of deceased and survived patients yielded significant
differences in the MELD score (including creatinine, INR),
hematocrit, albumin, TF, and AHSG values (Table 1). We
used multiple logistic regression analysis in order to
adjust for the effect of these confounding variables (TablePage 3 of 9
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els and 1-year mortality was found even after adjustment
for the confounding parameters listed above both in the
model including creatinine and INR and in the one using
MELD instead.
Analysis of survival between months 1 and 12
We have previously demonstrated that low serum AHSG
levels are associated high mortality during one-month fol-
low-up period [11]. As Figure 2 shows 14 out the 37 fatal-
ities occurred in the first month. In order to focus on the
utility of AHSG levels between the 1st and the 12th months
we re-run our analyses following exclusion of data of
patients who died in the first month.
Only creatinine, INR, albumin, TF, AHSG levels, the CP
and MELD scores differed significantly between deceased
and survived patients (Table 1, Column B). In this obser-
vation period only hematocrit (r = 0.368, p = 0.004), INR
(r = -0.404, p < 0.001), albumin (r = 0.331, p = 0.007), TF
(r = 0.499, p < 0.001), the MELD (r = -0.271, p = 0.018)
and CP (r = -0.431, p < 0.001) scores correlated with
AHSG values significantly. Low AHSG levels were still
associated with an elevated mortality rate and a high rela-
tive risk to die after the first month of observation (Table
3B).
The Kaplan-Meyer test showed a strong difference
between survivals of patients with low or high initial
AHSG values (Figure 3). The calculated mean survival
time with AHSG levels below and above 365 μg/ml was 5
± 1 months (mean ± S.E., 95% C.I.: 4 – 6) and 11 ± 0
months (95% C.I.: 11 – 12, p < 0.001), respectively (log
rank analysis). Life table analysis resulted in a median sur-
vival of 4.81 months in the former and over 12 months in
the latter group, respectively (p = 0.001).
The association between low serum AHSG level and 1–12-
month mortality was further analysed by a multiple logis-
tic regression, in which data were adjusted for the con-
founding variables that significantly differed between
deceased and survived patients (hematocrit, creatinine,
INR, albumin, TF). AHSG levels had significant p values in
the model using creatinine and INR and in the one using
MELD instead. When data were adjusted for the con-
founding variables a significant regression coefficient was
Table 1: Comparison of laboratory parameters of deceased and survived patients with alcoholic liver cirrhosis during the one-year 
follow-up period (Column A) and between months 1 and 12 (Column B)
(A) 1-year follow-up period (B) Follow-up between months 1–12
Parameter Deceased patients 
mean ± SD n = 37
Survived patients 
mean ± SD n = 52
p Deceased patients 
mean ± SD n = 23
Survived patients 
mean ± SD n = 52
p
Age, years 57 ± 14 52 ± 12 0.056 58 ± 15 52 ± 12 0.056
Erythrocyte sedimentation rate, mm/h 57 ± 32 40 ± 30 0.019 59 ± 34 40 ± 30 0.030
Hematocrit, l/l 0.32 ± 0.1 0.37 ± 0.1 0.004 0.33 ± 0.1 0.36 ± 0.1 0.029
Hemoglobin, g/l 112 ± 18 121 ± 24 0.053 113 ± 18 121 ± 24 0.137
White blood cell count, μl-1 9582 ± 5076 7706 ± 4640 0.016 8960 ± 5102 7706 ± 4639 0.082
Granulocyte count, μl-1 6308 ± 4080 4788 ± 3241 0.080 5409 ± 3253 4787 ± 3240 0.311
Platelet count, μl-1 16061 ± 117289 177370 ± 91742 0.228 153480 ± 114813 177370 ± 91742 0.185
Serum creatinine, mg/dl 1.31 ± 0.65 0.96 ± 0.29 0.002 1.32 ± 0.62 0.97 ± 0.28 0.001
Serum bilirubin, mg/dl 10.7 ± 1.0 6.90 ± 10.1 0.008 7.8 ± 1.3 7.13 ± 171 0.041
Serum aspartate aminotransferase, U/l 113 ± 80 122 ± 171 0.201 107 ± 81 122 ± 10 0.485
Serum alanine aminotransferase, U/l 79 ± 137 143 ± 351 0.852 97 ± 173 142 ± 350 0.763
Alkaline phosphatase, U/l 425 ± 422 371 ± 284 0.987 404 ± 479 371 ± 283 0.571
INR 1.73 ± 0.7 1.25 ± 0.4 < 0.001 1.64 ± 0.7 1.26 ± 0.4 < 0.001
Total protein, g/l 63 ± 7 68 ± 10 0.453 68 ± 7 68 ± 9 0.815
Albumin, g/l 31 ± 7 37 ± 6 0.001 31 ± 7 36 ± 7 0.008
CRP, mg/l 62 ± 78 42 ± 78 0.061 65 ± 103 43 ± 79 0.505
α2-macroglobulin, mg/dl 315 ± 87 339 ± 123 0.588 335 ± 97 340 ± 123 0.851
Haptoglobin, mg/dl 186 ± 260 201 ± 150 0.035 203 ± 280 200 ± 151 0.108
Transferrin, mg/dl 148 ± 52 216 ± 86 < 0.001 148 ± 60 217 ± 87 0.003
α1-acid glycoprotein, mg/dl 94 ± 51 112 ± 53 0.049 93 ± 54 112 ± 54 0.076
CP score 11 ± 2 7 ± 2 < 0.001 11 ± 2 8 ± 2 < 0.001
MELD score 20 ± 9 13 ± 5 < 0.001 20 ± 8 13 ± 6 < 0.001
AHSG, μg/ml 293 ± 77 490 ± 106 < 0.001 303 ± 91 490 ± 91 < 0.001
p: significance calculated by the Mann-Whitney testPage 4 of 9
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Table 2: Comparison of the sensitivity, specificity and predictive values of CP, MELD scores and serum AHSG in patients with alcoholic 
liver cirrhosis
(A) 1-year follow-up period (B) Follow-up between months 1–12
CP score
AUC ± SD 0.865 ± 0.040 0.855 ± 0.050
p < 0.001 < 0.001
95% C.I. 0.787 – 0.943 0.757 – 0.953
MELD score
AUC ± SD 0.739 ± 0.052 0.740 ± 0.058
p < 0.001 0.001
95% C.I. 0.637 – 0.871 0.626 – 0.854
Serum AHSG
AUC ± SD 0.937 ± 0.025 0.908 ± 0.035
p < 0.001 0.001
95% C.I. 0.889 – 0.986 0.839 – 0.978
CP score < 10, ≥ 10
Relative Risk 3.878 4.838
p < 0.001 < 0.001
95% C.I. 1.998 – 7.527 2.009 – 11.649
Sensitivity at this cutoff value 0.753 0.675
Specificity at this cutoff value 0.827 0.755
MELD score < 20, ≥ 20
Relative Risk 2.205 2.4167
p 0.002 0.011
95% C.I. 1.318 – 3.689 1.229 – 4.952
Sensitivity at this cutoff value 0.595 0.587
Specificity at this cutoff value 0.729 0.720
AHSG < 365 μg/ml, ≥ 365 μg/ml
Relative Risk 9.874 9.257
p < 0.001 < 0.001
95% C.I. 4.258 – 22.898 3.945 – 21.724
Sensitivity at this cutoff value 0.865 0.783
Specificity at this cutoff value 0.942 0.936
AHSG < 300 μg/ml, ≥ 300 μg/ml
Relative Risk 4.209 4.813
p < 0.001 < 0.001
95% C.I. 2.675 – 6.622 2.813 – 8.233
Sensitivity at this cutoff value 0.594 0.478
Specificity at this cutoff value 0.981 0.972
Table 3: Effect of initial serum AHSG level on the survival of patients with alcoholic liver cirrhosis throughout the 1-year observation 
period (A) and between months 1–12 (B)
A
Deceased Survived Total Mortality rate %
Serum AHSG < 365 μg/ml 32 3 35 94.1
Serum AHSG ≥ 365 μg/ml 5 49 54 9.3
Total 37 52 89
p < 0.001, Relative Risk: 9.874 (95% C.I.: 4.258 – 22.898)
B
Deceased Survived Total Mortality rate %
Serum AHSG < 365 μg/ml 18 3 21 85.7
Serum AHSG ≥ 365 μg/ml 5 49 54 9.3
Total 23 52 75
p < 0.001, Relative Risk: 9.257 (95% C.I.: 3.945 – 21.724)
BMC Gastroenterology 2007, 7:15 http://www.biomedcentral.com/1471-230X/7/15still found between AHSG levels and 1–12 month mortal-
ity both in the model with creatinine and INR and in the
one with MELD (Table 5Column B).
Comparison of the predictive accuracies of the CP, MELD 
scores and serum AHSG concentration
On ROC curve analysis the area under curve (AUC) of
serum AHSG exceeded those of the CP and MELD scores
(Table 2). The sensitivity and specificity of these cutoff
AHSG values were still above those of CP and MELD.
In accordance with most observations we stratified our
patients at the CP score of 10 [14,15]. The MELD score
value ≥20 is generally accepted as an indication for liver
transplantation [16]. Therefore we stratified MELD at 20.
Patients with MELD ≥ 20 had higher relative risk to die
within a year than those with smaller values but this risk
was below what we found for AHSG < 365 μg/ml (Table
2). The risk of lethal outcome in patients with CP < 10 was
comparable with those of low baseline AHSG values.
Figure 4 illustrates the significant difference between sur-
vival of patients with MELD < 20 or ≥ 20 and serum AHSG
> or ≥ 365 μg/ml. In order to analyse the joint effect of
MELD and serum AHSG on survival of patients with liver
cirrhosis patients were divided to four groups according to
these critical values. Compared to group 1 (MELD < 20
and serum AHSG ≥ 365 μg/ml) group 2 (MELD < 20 and
serum AHSG < 365 μg/ml) had a significantly shortened
survival: 5 ± 1 months, 95% C.I.: 3–6 months vs. 12
months, 95% C.I. 11 – 12 months (log rank analysis: p <
0.001). The survival of patients in group 3 (MELD ≥ 20
and serum AHSG ≥ 365 μg/ml) was also reduced (mean
survival time: 8 ± 2 months, 95% C.I.: 5 – 11 months, log
rank analysis: p = 0.008. Group 4 (MELD ≥ 20 and serum
AHSG < 365 μg/ml) had the worst prognosis: mean sur-
vival time: 2 ± 1 months (95% C.I.: 1 – 3 months, log rank
analysis: p = 0.00001. Survival between groups 3 and 4
also differed significantly (p = 0.001).
Finally we set up a multiple logistic regression model to
compare the predictive values of serum AHSG concentra-
tion to those of the CTP and MELD scores (Table 6).
Serum AHSG values had the strongest association with
mortality.
Discussion
Previously we found serum AHSG to be an outstanding
laboratory parameter of liver function an independent
predictor of short-term mortality during the 1-month fol-
low-up period [11]. Data gained during the first month of
the present study supported our previous observations on
short-term survival. Our present data suggest that the ini-
Table 4: Fatality risk over the one-year observation period in patients with serum AHSG levels above and below 365 μg/ml
Hazard rate at AHSG < 365 μg/ml AHSG ≥ 365 μg/ml
1 month 0.500 ± 0.129 0.000 ± 0.000
3 months 0.897 ± 0.222 0.077 ± 0.384
6 months 0.909 ± 0.362 0.020 ± 0.000
12 months and after* 0.943 ± 0.420 0.000 ± 0.000
* Since the observation period was limited to 12 months hazard rate at this time interval should be considered as an interpolation. Hazard rate: 
mean ± SE
Patients with serum AHSG concentration < 365 μg/ml have low r survival rate than those with ≥ 365 μg/ml throug outthe 1-year ob vation periodFigu e 1
Patients with serum AHSG concentration < 365 μg/
ml have lower survival rate than those with ≥ 365 μg/
ml throughout the 1-year observation period. Serum 
AHSG concentration < 365 μg/ml (green line, n = 35), serum 
AHSG concentration ≥ 365 μg/ml (magenta line, n = 54), log 
rank test, p < 0.001Page 6 of 9
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long-term mortality as well. Excluding fatal outcomes that
occurred during the first month survival analysis showed
that low serum AHSG levels were still markedly associated
with mortality. The marked difference of mean survival
time between patients with low and normal AHSG levels
indicated by the Kaplan-Meyer and life table analysis were
in complete accordance with these observations.
The proinflammatory cytokines interleukin (IL)-1, IL-6,
and tumour necrosis factor-α (TNFα) are known to
enhance the synthesis of the positive (CRP, OROSO) and
down-regulate that of the negative acute phase reactants
in rat liver and human HepG2 cells [17,18]. Our short-
term follow-up results suggested that the decreased serum
AHSG concentration was associated rather with hepato-
cyte dysfunction than with the acute phase reaction [11].
During the 1-year follow up, a strong positive correlation
with the negative acute phase protein TF and a negative
correlation with the positive acute phase protein CRP
have been observed. This latter correlation, however, was
not significant between months 1–12. We found no sig-
nificant correlation with the positive acute phase reactant
OROSO. This suggests that the acute phase reaction is nei-
ther a determinant of the concentration of these proteins
nor affects the long-term outcome in patients with liver
cirrhosis. Thus, in accordance with our earlier findings
low serum AHSG concentration reflects rather hepatocyte
dysfunction than the acute phase reaction [11].
It has to be mentioned, however, that serum AHSG con-
centration is not decreased in every liver disease. There is
no change in acute A, B, or Epstein-Barr virus hepatitis,
and, moreover, there is a paradoxic elevation of AHSG lev-
els in sera of patients with chronic C virus hepatitis
[11,12,19]. Therefore serum AHSG concentration has
probably no prognostic significance in these diseases.
Since its introduction in 2001 the MELD score has been
used widely to predict the outcome of patients with end-
Table 5: Association of low fetuin A/α 2HS-glycoprotein levels with 1-year mortality of patients with alcoholic liver cirrhosis calculated 
by adjusted multiple logistic regression*
(A) 1-year follow-up period (B) Follow-up between months 1–12
Variable p* p* p* p*
Hematocrit 0.482 0.597 0.463 0.453
Serum albumin 0.271 0.832 0.249 0.994
Transferrin 0.706 0.838 0.608 0.843
Serum creatinine - 0.633 - 0.806
INR - 0.290 - 0.262
MELD < 20, ≥ 20 0.172 - 0.165 -
AHSG < 365 μg/ml, ≥ 365 μg/ml 0.004 0.010 0.021 0.012
Odds Ratio of AHSG < 365 μg/ml, ≥ 365 μg/
ml
58.82 95% C.I.: 3.703 – 950.8 49.35 95% C.I.: 2.497 – 975.6 28.91 95% C.I: 1.661 – 503.4 32.59 95% C.I.: 1.502 – 707.0
Model fit p = 0.015 p = 0.068 p = 0.002 p = 0.012
* P value of regression coefficient, adjusted for variables significantly associated with mortality at univariate analysis (Table 1)
Serum AHSG concentration did not change considerably du ing the 1-year observation periodFig re 2
Serum AHSG concentration did not change consid-
erably during the 1-year observation period. Values 
represent mean ± SEM. Comparison was performed by the 
Wilcoxon test. Baseline values of patients who died during 
the first month of observation (n = 14) were omitted from 
the analysis.Page 7 of 9
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of MELD and its comparison to the classical CP score have
been reviewed extensively [14,15]. Though the clinical
usefulness of MELD is established well modifications
have been still recommended [20]. We have also found
that CP performs slightly better than MELD. Logistic
regression studies indicate that the CP, MELD and serum
AHSG levels predict mortality somewhat independently
from each other.
Conclusion
The sensitivity, specificity and predictive values of serum
AHSG concentration exceed those of the CP and the
MELD scores. Although not in wide use the measurement
serum AHSG concentration is simple. Serum AHSG levels
may add to the power of MELD. A study performed on a
large series of patients is needed to decide whether the
combination of these parameters will result in an
improved predictive value, and if so, how serum AHSG
levels could be formulated.
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The joint effect of serum AHSG concentration and the MELD score on the survival of patients with alcoholic liver cirrh sisFigure 4
The joint effect of serum AHSG concentration and 
the MELD score on the survival of patients with alco-
holic liver cirrhosis. Group 1 (green line): MELD < 20, 
serum AHSG ≥ 365 μg/ml (n = 46), group 2 (magenta line): 
MELD < 20, serum AHSG < 365 μg/ml (n = 16), group 3 (yel-
low line): MELD ≥ 20, serum AHSG ≥ 365 μg/ml (n = 7), and 
group 4 (grey line): MELD ≥ 20, serum AHSG < 365 μg/ml (n 
= 20), respectively. Compared to group 1, the survival is sig-
nificantly shortened in groups 2, 3, and 4. Compared to 
group 1 the Odds Ratios for lethal outcome in groups 2, 3, 
and 4 are: 157.5 (95% C.I.: 20.28 – 1223, p < 0.001), 16.875 
(95% C.I.: 2.149 – 132.5, p = 0.012), and 405.0, 95% C.I.: 
34.53 – 4749 p < 0.0001), respectively.
Patients with serum AHSG concentration < 365 μg/ml have low r survival rate than those with ≥ 365 μg/ml between month  1–12Figu e 3
Patients with serum AHSG concentration < 365 μg/
ml have lower survival rate than those with ≥ 365 μg/
ml between months 1–12. Serum AHSG concentration < 
365 μg/ml (green line, n = 21), serum AHSG concentration ≥ 
365 μg/ml (magenta line, n = 54), log rank test p < 0.001Page 8 of 9
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Table 6: Association of serum AHSG concentration, the CTP and MELD scores with mortality of patients with alcoholic liver cirrhosis 
calculated by adjusted multiple logistic regression
1-year follow-up Months 1–12
Variable p* OR 95% C.I. p* OR 95% C.I.
CTP score < 10, ≥ 10 0.004 17.54 0.005 15.58
2.556 – 119.9 2.333 – 104.1
MELD score < 20, ≥ 20 0.110 - 0.120 -
AHSG < 365 μg/ml, ≥ 365 < 0.001 170.6 < 0.001 89.43
μg/ml 22.73 – 1280 11.89 – 672.6
Model fit p = 0.114 p = 0.001
*: p value of regression coefficientPage 9 of 9
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